News

Get the latest on BIO's announcements, positions and views on everything from healthcare to biofuels. 

Press Releases
BIO Urges Biden Administration to Work Alongside…
The Biotechnology Innovation Organization (BIO) released the following statement in response to a bipartisan letter signed by 21 members of the U.S. House of Representatives. Led by Reps. Randy Feenstra (R-IA) and Dan Kildee (D-MI), the letter urged…
Virginia Governor Glenn Youngkin named BIO’s…
WASHINGTON, DC (September 17, 2024) – Today, the Biotechnology Innovation Organization (BIO) awarded Virginia Governor Glenn Youngkin with its 2024 Governor of the Year Award. BIO’s annual award honors governors for their leadership and…
New Season of “I am BIO” Podcast Explores Patient…
WASHINGTON - (September 5, 2024) –The Biotechnology Innovation Organization (BIO) will launch the fall season of the award-winning “I am BIO” podcast on September 10. Now entering its fifth year, the podcast explores the intersection of…
Letters, Testimony, & Comments
ohn’s One-Year Anniversary Letter to BIO…
Dear Colleagues,This month marks my one-year anniversary as BIO’s CEO. Like most of us in biotech, this post has been a labor of love. At no time in my 25-year career in this industry have I ever witnessed such awe-inspiring science. Today, we…
BIO Comments on Office of Management and Budget …
Re: BIO Comments on Office of Management and Budget (OMB) Statistical Policy Directive No. 8 North American Industry Classification System (NAICS)-Request forComments on Possible Revisions for 2027 (USBC–2024–0032)Dear Ms. Orvis,The Biotechnology…
BIO Letter to HRSA on 340B Rebate Model
Under the 340B program, participating manufacturers must offer 340B pricing on their covered outpatient drugs by covered entities, as a condition of having those drugs federally payable under Medicare Part B and Medicaid. Critically, Congress…
Amicus Briefs
BIO Files Amicus Brief in Continuing Effort to…
BIO filed an amicus brief in a continuing effort to challenge courts' decisions that undermine FDA authority and hinder patient access to medications.The brief was filed in the Supreme Court of the United States (SCOTUS), following the August 2023…
BIO Files Amicus Brief Supporting Reversal of…
BIO filed an amicus brief in the U.S. Court of Appeals for the Sixth Circuit, seeking the reversal of a lower court's ruling that would set aside the 2022 rescission of the Securities and Exchange Commission (SEC) 2020 Rule regulating proxy advisory…
BIO Files Amicus Brief Urging Harmonization of…
BIO filed an amicus brief in the U.S. Court of Appeals for the Federal Circuit on an important and recurring question concerning the framework for determining patent obviousness in patent litigation. BIO argues that courts, when considering whether…